Elodep 10 mg (Tablet)

Unit Price: ৳ 12.00 (3 x 10: ৳ 360.00)

Strip Price: ৳ 120.00

Medicine Details

Orally administered selective serotonin reuptake inhibitor (SSRI)
Pure S-enantiomer of the racemic bicyclic phthalate derivative citalopram
At least 100 fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake
No or very low affinity for serotonergic or other receptors including alpha- and beta-adrenergic Dopamine, Histamine, Muscarinic and benzodiazepine receptors

Safety of daily doses above 20 mg has not been demonstrated
Escitalopram Oxalate is administered as a single daily dose and may be taken with or without food
Usual dosage is 10 mg once daily for major depressive episodes
An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg daily for panic disorder with or without agoraphobia
Usual dosage is 10 mg once daily for social anxiety disorder
Initial dosage is 10 mg once daily for generalised anxiety disorder
Initial dosage is 10 mg once daily for obsessive-compulsive disorder

Escitalopram should generally be administered once daily, morning or evening with or without food

SSRI or related antidepressants should not be started until 2 weeks after stopping an MAOI
An MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped

Escitalopram is contraindicated in patients with known hypersensitivity to Escitalopram or Citalopram or any of the inactive ingredients of the drug product
Concomitant use of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated

SSRIs are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants
Gastrointestinal effects include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, and constipation
Anorexia with weight loss and increased appetite and weight gain
Hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity
Other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances

When treating a pregnant woman with Escitalopram during the third trimester, the physician should carefully consider the potential risks and benefits of treatment
It is excreted in human breast milk
The decision whether to continue or discontinue either nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the infant and the benefits Escitalopram treatment for the mother

SSRIs should be used with caution in patients with epilepsy, cardiac disease, diabetes mellitus, angle-closure glaucoma, and history of bleeding disorders
SSRIs should be avoided in poorly controlled epilepsy, concurrent electroconvulsive therapy, history of mania, concomitant use of drugs that increase risk of bleeding, and hepatic and renal impairment

Elderly patients (>65 years of age): Initial dosage is 5 mg once daily and may be increased to 10 mg daily
Children and adolescents (<18 years): Elodep should not be used in the treatment of children and adolescents under the age of 18 years
Reduced renal function: Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Caution is advised in patients with severely reduced renal function (CLCR less than 30 ml/min)
Reduced hepatic function: An initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to 10 mg daily
Poor metabolizers of CYP2C19: For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended

Symptoms include dizziness, tremor, agitation, serotonin syndrome, convulsion, coma, nausea/vomiting, hypotension, tachycardia, QT interval prolongation, arrhythmia, hypokalaemia, hyponatremia
There is no specific antidote; general symptomatic supportive measures should be taken
ECG monitoring is advised in case of overdose, in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT-interval, or in patients with altered metabolism, e.g. liver impairment